SequelSEC

COGNITION THERAPEUTICS INC CGTX

Biological Products, (No Diagnostic Substances) · CIK 0001455365 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$47.80M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$18.16MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.20Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio3.45x39th

COGNITION THERAPEUTICS INC (CGTX) reported net income of -$23.49M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from COGNITION THERAPEUTICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

COGNITION THERAPEUTICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$47.80M-$53.97M-$50.72M-$43.55M-$28.60M-$17.41M
Net income-$23.49M-$33.97M-$25.79M-$21.40M-$11.72M-$7.84M
Research & development$37.19M$41.68M$37.20M$30.32M$18.57M$12.89M
Weighted-average diluted sharesshares 72.77Mshares 39.73Mshares 30.03Mshares 23.64Mshares 5.19MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0Unavailable
Diluted EPS$-0.32$-0.86$-0.86$-0.91$-3.13$-23.76
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.61M$12.29M$13.53M$13.23M$10.03M$4.52M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

COGNITION THERAPEUTICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$36.81M$25.01M$29.92M$41.56M$54.72M$5.19M
Total assets$48.39M$30.23M$35.16M$50.42M$59.14M$7.12M
Current assets$47.99M$29.56M$34.22M$47.65M$58.99M$6.91M
Total liabilities$14.12M$11.48M$10.69M$10.18M$7.86M$19.93M
Current liabilities$13.92M$11.14M$10.17M$7.80M$7.86M$3.25M
Total equity incl. NCI$34.27M$18.75M$24.47M$40.25M$51.27M-$68.18M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$55.37M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.12M$1.98M$3.70M$3.22M$4.17M$2.00M

Cash flow

COGNITION THERAPEUTICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$24.59M-$28.47M-$16.02M-$18.53M-$3.63M-$3.43M
Capital expendituresUnavailable$4.00K$147.00K$171.00K$27.00K$10.00K
Investing cash flow$9.00K-$4.00K-$147.00K-$171.00K-$27.00K-$10.00K
Financing cash flow$36.57M$23.56M$4.52M$5.55M$53.20M$5.76M
Net change in cash$11.99M-$4.91M-$11.64M-$13.16M$49.53M$2.30M
Stock-based compensation$2.09M$3.75M$4.35M$3.57M$5.18M$475.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$36.00K$107.00K$96.00K$83.00K$93.00K$98.00K

Derived

COGNITION THERAPEUTICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailable-$28.48M-$16.16M-$18.70M-$3.66M-$3.44M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio3.45x2.65x3.37x6.11x7.50x2.13x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CGTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.